Evidence mapPaperPMID 23624546Full record

ArticleDiabetologia2013

Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).

W E Boertien, I J Riphagen, I Drion, A Alkhalaf, S J L Bakker, K H Groenier, J Struck, P E de Jong, H J G Bilo, N Kleefstra and 1 more

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Diabetologia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03917758 naunknown statusstarted 2018, after this paper: background citation

Assessment of the Renin-angiotensin-aldosterone System (RAAS) and Antidiuretic Function in Patients With Type 2 Diabetes Before and During Treatment With Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i): the GliRACo 1 Study

Ran2018Enrolled30Registered outcomes24Posted comparisons0ConditionsArterial Hypertension, Body Weight Changes, Diabetes Mellitus, Type 2ArmsSGLT2 inhibitor
Open the trial in the graph
NCT07789847 narecruitingnot on this mapstarted 2026, after this paper: background citation

Does Altering Daily Fluid Intake and Hydration Status Influence Cortisol Reactivity to Acute Psychosocial Stress?

TypeinterventionalSponsorLiverpool John Moores UniversityRan2026 to 2027Enrolled192ConditionsHydration Status, Psychosocial Stress, Fluid IntakeArmsModifying daily total fluid intake
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Approach to the Patient: "Utility of the Copeptin Assay".The Journal of clinical endocrinology and metabolism · 2022
    Article
  12. Novel Cardiovascular Risk Factors in Patients with Diabetic Kidney Disease.International journal of molecular sciences · 2021
    Review
  13. Review
  14. Review
  15. Article
  16. The Emerging Role of Copeptin.The Clinical biochemist. Reviews · 2021
    Review
  17. Review
  18. Review
  19. Article
  20. Vasopressin and Copeptin in health and disease.Reviews in endocrine & metabolic disorders · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

W E BoertienDepartment of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. w.e.boertien@umcg.nl
I J Riphagen
I Drion
A Alkhalaf
S J L Bakker
K H Groenier
J Struck
P E de Jong
H J G Bilo
N Kleefstra
R T Gansevoort
University of Groningen · NLIsala · NLDialyse Centrum Groningen · NLThermo Fisher Scientific (Germany) · DEUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aim/hypothesisArginine vasopressin (AVP), the hormone important for maintaining fluid balance, has been shown to cause kidney damage in rodent models of diabetes. We investigated the potential role of AVP in the natural course of kidney function decline in diabetes in an epidemiological study.

methodsPlasma copeptin, a surrogate for AVP, was measured in baseline samples from patients with type 2 diabetes treated in primary care and included in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) cohort.

resultsSamples from 1,328 patients were available; 349 were analysed separately because they used renin-angiotensin-aldosterone system inhibition (RAASi), which influences albumin/creatinine ratio (ACR) and estimated (e)GFR. In the other 979 patients (46% men, age 68 years [58-75], ACR 1.8 mg/mmol [0.9-5.7], eGFR 67 ± 14 ml min(-1) 1.73 m(-2)) baseline copeptin (5.3 pmol/l [3.2-9.5]) was significantly associated with log e [ACR] and eGFR, even after adjustment for sex, age and risk factors for kidney function decline (standardised [std] β 0.13, p < 0.001, std β -0.20, p < 0.001 respectively). Follow-up data were available for 756 patients (6.5 years [4.1-9.6]). Baseline copeptin was associated with increase in ACR (std β 0.09, p = 0.02), but lost significance after adjustment (std β 0.07, p = 0.08). Copeptin was associated with a decrease in eGFR after adjustment (std β -0.09, p = 0.03). The strength of the association of copeptin with change in eGFR was stronger than that of established risk factors for kidney function decline (e.g. BMI, HbA1c). In patients who used RAASi there was a significant association between baseline copeptin and ACR and eGFR, but not with change in ACR and eGFR. CONCLUSIONS/

interpretationIn patients with diabetes not using RAASi a higher baseline copeptin concentration is significantly associated with higher baseline ACR and lower eGFR values and with a decline in eGFR during follow-up. This last association is independent of, and stronger than, most traditional risk factors for kidney function decline.

Indexed as

AgedAlbuminsAngiotensin-Converting Enzyme InhibitorsArginine VasopressinBiomarkersCreatinineCross-Sectional StudiesDiabetes Mellitus, Type 2FemaleGlomerular Filtration RateGlycopeptidesHumansMaleMiddle AgedRenin-Angiotensin SystemAlbuminsAngiotensin-Converting Enzyme InhibitorsArginine VasopressinBiomarkerscopeptinsCreatinineGlycopeptides

Identifiers

PMID23624546
OpenAlexW2169518471

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.